Welcome to our dedicated page for Bionano Genomics news (Ticker: BNGO), a resource for investors and traders seeking the latest updates and insights on Bionano Genomics stock.
Stay informed about Bionano Genomics news and developments in optical genome mapping technology. News coverage tracks the company's clinical validation studies, instrument installations, diagnostic services expansion, regulatory milestones, reimbursement developments, and research collaborations advancing genomic analysis capabilities.
Significant news categories include clinical study publications demonstrating the utility of optical genome mapping for detecting chromosomal abnormalities in hematologic malignancies and genetic disorders, announcements of new customer installations at academic medical centers and reference laboratories, and presentations at scientific conferences showcasing applications across oncology, cytogenetics, and reproductive genetics. Coverage of reimbursement policy developments, including establishment of CPT billing codes and insurance coverage decisions, impacts clinical adoption and market access for the company's diagnostic testing services.
Research collaboration announcements highlight partnerships with leading medical institutions validating optical genome mapping performance compared to conventional cytogenetic methods. Product development news covers enhancements to the Saphyr and Stratys instrument platforms, software updates to the VIA genome analysis solution, and expansion of the consumables portfolio. Regulatory clearances and quality certifications for clinical laboratory operations represent important milestones for diagnostic services growth.
Corporate developments including financial results, strategic initiatives, analyst coverage, and leadership appointments provide insight into the company's business trajectory and market position within the genomics industry. Partnership announcements with pharmaceutical companies, diagnostic laboratories, and technology providers indicate commercial momentum and expanding applications for optical genome mapping across precision medicine workflows.
Bionano Genomics (BNGO) announced a significant milestone for its Saphyr System with a new software update increasing annual throughput by 1,400% from 384 to nearly 5,000 human genomes. The update allows for imaging up to 96 genomes weekly at a 100x coverage depth. New features include Saphyr Assure, an automated health monitoring tool for data quality. This advancement supports high-volume settings like discovery research and cytogenomics, and comes pre-installed on new systems while being available to existing users free of charge.
Bionano Genomics (Nasdaq: BNGO) announced a pivotal publication in the Proceedings of the National Academy of Sciences, detailing how the Saphyr system effectively characterizes the integration of human herpesvirus 6 (HHV-6) within the human genome. This international collaboration demonstrated that traditional molecular techniques failed to pinpoint the viral integration sites, highlighting Saphyr's unique capabilities in imaging long DNA sequences. CEO Erik Holmlin emphasized the significance of this research in understanding HHV-6's impact on human health, as its integration can lead to various diseases.
Bionano Genomics (BNGO) is showcasing its Saphyr System as a diagnostic tool for hematologic malignancies at the ASH Annual Meeting. Dr. Rashmi Kanagal-Shamanna from MD Anderson will present on Saphyr's performance in Myelodysplastic Syndrome (MDS). Additionally, Dr. Barbara Dewaele will discuss a validation study for Acute Lymphoblastic Leukemia (ALL). The conference takes place from December 5-8, focusing on advancements in genomic diagnostics.
Bionano Genomics announced that its Saphyr system for optical genome mapping is being highlighted at the Annual Meeting of the Association for Molecular Pathology (AMP) from November 16-20, 2020. The event focuses on advancements in molecular diagnostics, with Bionano showcasing its technology in various presentations, including a corporate workshop. The application of the Saphyr system spans multiple clinical applications, especially in complex genetic disorders and heme malignancies, marking a significant step in molecular pathology education.
Bionano Genomics (NASDAQ: BNGO) reported Q3 2020 financial results, with total revenue of $2.2 million, an 86% sequential increase but down 33.7% year-over-year. The decrease is attributed to a change in revenue mix. Operating expenses rose to $11 million, driven by acquisition-related costs and increased workforce. Bionano completed the acquisition of Lineagen and received accolades for Saphyr as a first-line tool for leukemia diagnostics. Cash and equivalents stood at $18.9 million, up from $17.3 million at year-end 2019. A conference call to discuss the results is scheduled for November 12.
Bionano Genomics announced a study demonstrating that its Saphyr system achieved 100% concordance with standard methods for detecting structural variants (SVs) and copy number variants (CNVs) in 100 acute myeloid leukemia (AML) samples. Additionally, Saphyr provided extra actionable insights in 24% of cases, suggesting it may serve as a first-line test. The study, led by experts from prestigious institutions, highlights Saphyr's advantages over karyotyping, including better performance and cost-effectiveness. The findings may influence future medical guidelines and promote broader clinical adoption.
Bionano Genomics announced the publication of a study from UCSF demonstrating its optical genome mapping technology's superiority over whole exome sequencing (WES) and chromosomal microarray (CMA) in diagnosing rare genetic disorders. In a cohort of 50 patients, the technology provided definitive diagnoses for 12% and identified candidate pathogenic variants in 20% of cases. The study indicates Bionano's Saphyr system could enhance patient diagnosis rates, favoring widespread adoption of its genetic analysis tools in clinical settings.
Bionano Genomics, Inc. (Nasdaq: BNGO) announced significant advancements in cancer predisposition and genetic disorders using its Saphyr system. Presentations at the American Society of Human Genetics (ASHG) Annual Meeting from October 27-30, 2020, showcase 18 studies highlighting Saphyr's utility in analyzing structural variations in various diseases. CEO Erik Holmlin noted an increasing recognition of Saphyr's capabilities, potentially boosting adoption in genetic research and clinical studies.
Bionano Genomics announced Dr. Erich Jarvis as a co-principal investigator for the COVID-19 Host Genome SV Consortium. This partnership aims to analyze structural variants in genomes to identify COVID-19 risk markers and treatment methods. The study compares genomes of sensitive animal species and human patients who suffered severe COVID-19 against those resistant to the virus. Bionano's Saphyr system is central to generating precise genome assemblies critical for this research, potentially leading to improved treatments and vaccines.
Bionano Genomics (NASDAQ: BNGO) has announced a significant update to its Saphyr software tools for genomic analysis, enhancing capabilities in structural variation detection. The update includes over 100 new features to improve workflow efficiency, with new functionalities designed for clinical labs tackling genetic diseases and cancers. Notably, these improvements aim to increase the adoption of Saphyr technology in approximately 2,500 cytogenetics labs globally. The update is available as a free download and is expected to facilitate accelerated development of diagnostic tests.
FAQ
What is the current stock price of Bionano Genomics (BNGO)?
What is the market cap of Bionano Genomics (BNGO)?
